RARA and acute myeloid leukemia: Until recently, the great majority of patients were treated with conventional chemotherapy, and the only targeted drug used in routine clinical practice was all-trans retinoic acid (atRA), which is highly effective in a subgroup of AML characterized by rearrangements of the retinoic acid (RA) receptor, RARA [5–7].